tiprankstipranks
Advertisement
Advertisement

EBR Systems schedules investor webinar to discuss Q1 2026 results

Story Highlights
  • EBR Systems will host an investor webinar to review its first-quarter 2026 financial and operating results.
  • The company aims to bolster its position in cardiac rhythm management as it progresses commercialization of its WiSE wireless pacing technology.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
EBR Systems schedules investor webinar to discuss Q1 2026 results

Claim 55% Off TipRanks

EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:EBR) ) has issued an update.

EBR Systems, developer of the WiSE wireless cardiac pacing technology, will hold an investor webinar to discuss its first-quarter 2026 results following the release of its Quarterly Activity Report and Form 10-Q. The session, led by senior management on 14 May 2026, underscores the company’s ongoing engagement with shareholders as it advances commercialisation of its left-ventricular pacing system, which remains investigational in most markets but is currently available for sale in the U.S.

The webinar will provide investors with an opportunity to hear management’s commentary on operating performance and strategic progress in the heart failure market. The update comes as EBR seeks to strengthen its position in cardiac rhythm management by promoting its leadless pacing approach, a technology designed to reduce complications associated with traditional pacing leads and potentially enhance adoption of cardiac resynchronisation therapy.

The most recent analyst rating on (AU:EBR) stock is a Buy with a A$2.43 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.

More about EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh

EBR Systems is a Silicon Valley-based medical technology company focused on treating cardiac rhythm disease with its proprietary Wireless Stimulation Endocardially (WiSE) technology. The company’s lead product is a wireless, endocardial left-ventricular pacing system aimed at improving cardiac resynchronisation therapy for heart failure patients, with future applications potentially extending to bradycardia and non-cardiac indications.

Average Trading Volume: 503,466

Technical Sentiment Signal: Sell

Current Market Cap: A$2.7B

Learn more about EBR stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1